Wells Fargo
ZBIO

Wells Fargo’s Zenas BioPharma ZBIO Stock Holding History

Wells Fargo’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Buy
25,995
+17,110
+193% +$340K ﹤0.01% 4415
2026
Q1 		$174K Sell
8,885
-12,266
-58% -$275K ﹤0.01% 4783
2025
Q4 		$768K Buy
21,151
+8,696
+70% +$286K ﹤0.01% 4166
2025
Q3 		$277K Buy
12,455
+2,031
+19% +$33.1K ﹤0.01% 4730
2025
Q2 		$101K Buy
10,424
+2,261
+28% +$22K ﹤0.01% 5189
2025
Q1 		$64.5K Buy
8,163
+181
+2% +$1.42K ﹤0.01% 5313
2024
Q4 		$65.4K Buy
+7,982
New +$125K ﹤0.01% 5399

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Wells Fargo's ZBIO Position: Q2 2026 in Review

Wells Fargo increased its Zenas BioPharma (ZBIO) stake by 193% in Q2 2026, buying an estimated $340K and bringing the position to 25,995 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #4415.

Wells Fargo first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $768K in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Wells Fargo held 25,995 shares of Zenas BioPharma worth $660K as of Q2 2026.
  • Wells Fargo bought 17,110 Zenas BioPharma shares in Q2 2026, an estimated $340K.
  • Zenas BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4415 holding.
  • Wells Fargo first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • Wells Fargo's Zenas BioPharma position peaked at $768K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.